Atlas Venture nets $350M in oversubscribed fundraise
June 30, 2017
Cambridge, MA | Venture Capital
Atlas Venture, a biotech-focused investor, has closed its latest namesake fund on $350 million. The firm raised $280 million for its previous flagship fund in 2015. Atlas' portfolio includes neonatal and pediatric pharmaceutical company InfaCare and Ataxion, a developer of small-molecule therapeutics designed to treat neurological diseases.